HomeCompareFTCHF vs PFE

FTCHF vs PFE: Dividend Comparison 2026

FTCHF yields 666666.67% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FTCHF wins by $8.275235618773884e+34M in total portfolio value
10 years
FTCHF
FTCHF
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full FTCHF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — FTCHF vs PFE

📍 FTCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFTCHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FTCHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FTCHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FTCHF
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, FTCHF beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FTCHF + PFE for your $10,000?

FTCHF: 50%PFE: 50%
100% PFE50/50100% FTCHF
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

FTCHF
Analyst Ratings
10
Buy
8
Hold
1
Sell
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FTCHF buys
0
PFE buys
0
No recent congressional trades found for FTCHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFTCHFPFE
Forward yield666666.67%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8.275235618773884e+34M$51.1K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$27,210.54
Total dividends collected$8.275075881065991e+34M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: FTCHF vs PFE ($10,000, DRIP)

YearFTCHF PortfolioFTCHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$66,677,367$66,666,666.67$9,161$701.38+$66.67MFTCHF
2$415,506,651,117$415,435,306,334.37$8,610$859.79+$415506.64MFTCHF
3$2,419,908,598,386,268$2,419,464,006,269,573.00$8,366$1,081.25+$2419908598.38MFTCHF
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$8,483$1,405.66+$13171697643084.45MFTCHF
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$9,084$1,907.24+$67004927492790120.00MFTCHF
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$10,418$2,732.78+$318562277003514871808.00MFTCHF
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$13,007$4,193.56+$1.415484168853553e+24MFTCHF
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$18,010$7,005.87+$5.878130573362507e+27MFTCHF
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$28,216$12,979.89+$2.2813793009840744e+31MFTCHF
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$51,081$27,210.54+$8.275235618773884e+34MFTCHF

FTCHF vs PFE: Complete Analysis 2026

FTCHFStock

Farfetch Limited, together with its subsidiaries, operates a platform for the luxury fashion industry in the United States, the United Kingdom, and internationally. It operates through three segments: Digital Platform, Brand Platform, and In-Store. The company operates The Farfetch Marketplace, a global digital luxury fashion marketplace that connects consumers from approximately 190 countries and territories with merchandise from sellers, including brands, boutiques and department stores; New Guards, a platform that designs, manufactures, and distributes luxury fashion brands; Browns, a fashion and luxury goods retailer; Stadium Goods, a premium sneaker and streetwear marketplace and retailer; and VioletGrey.com, Luxclusif, Farfetch Future Retail, and other online sales channel. It also offers Farfetch Platform Solutions comprising building and operation of e-commerce and technology solutions for luxury brands and retailers; and ancillary services, including digital marketing, production, and customer services. In addition, the company operates Browns, Stadium Goods, Violet Grey, Off-White, Palm Angels, Ambush, and other brand stores; and Farfetch app. Further, the company engages in the web design, build, development, and retail distribution for retailers and brands. Farfetch Limited was founded in 2007 and is headquartered in London, the United Kingdom.

Full FTCHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this FTCHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FTCHF vs SCHDFTCHF vs JEPIFTCHF vs OFTCHF vs KOFTCHF vs MAINFTCHF vs JNJFTCHF vs MRKFTCHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.